Do piperacillin/tazobactam and other antibiotics with inhibitory activity against Clostridium difficile reduce the risk for acquisition of C. difficile colonization?

BMC Infectious Diseases

Volumn 16, Issue 1, 2016, Pages

  Kundrapu, Sirisha ^a,b   Sunkesula, Venkata C K ^a   Jury, Lucy A ^c   Cadnum, Jennifer L ^a   Nerandzic, Michelle M ^a   Musuuza, Jackson S ^d   Sethi, Ajay K ^d   Donskey, Curtis J ^a,c  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Clostridium difficile; Colonization; Piperacillin tazobactam

Indexed keywords

AMPICILLIN; CARBAPENEM DERIVATIVE; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; IMIPENEM; LINEZOLID; MEROPENEM; METRONIDAZOLE; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; TETRACYCLINE; ANTIINFECTIVE AGENT; PENICILLANIC ACID; PIPERACILLIN; TAZOBACTAM;

ADULT; AGED; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL GROWTH; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; GROWTH INHIBITION; HUMAN; IN VITRO STUDY; INFECTION RISK; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PREVALENCE; RISK REDUCTION; ANALOGS AND DERIVATIVES; DRUG EFFECTS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECES; HOSPITAL; INTESTINE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PHYSIOLOGY; RISK FACTOR;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECES; HOSPITALS; HUMANS; INTESTINES; MICROBIAL SENSITIVITY TESTS; PENICILLANIC ACID; PIPERACILLIN; RISK FACTORS;

EID: 84963591032     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-016-1514-2     Document Type: Article

References (23)

1. Owens Jr RC, Donskey CJ, Gaynes RP, Loo VG, Muto CA. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis. 2008;46:19-31.
2. Settle CD, Wilcox MH, Fawley WN, Corrado OJ, Hawkey PM. Prospective study of the risk of Clostridium difficile diarrhea in elderly patients following treatment with cefotaxime or piperacillin-tazobactam. Aliment Pharmacol Ther. 1998;12:1217-23.
3. Wilcox MH, Freeman J, Fawley W, MacKinlay S, Brown A, Donaldson K, et al. Long-term surveillance of cefotaxime and piperacillin-tazobactam prescribing and incidence of Clostridium difficile diarrhea. J Antimicrob Chemother. 2004;54:168-72.
4. Valerio M, Pedromingo M, Muñoz P, Alcalá L, Marin M, Peláez T, et al. Potential protective role of linezolid against Clostridium difficile infection. Int J Antimicrob Agents. 2012;39:441-9.
5. Doernberg SB, Winston LG, Deck DH, Chambers HF. Does doxycycline protect against development of Clostridium difficile infection? Clin Infect Dis. 2012;55:615-20.
6. Wilcox MH. Evidence for low risk of Clostridium difficile infection associated with tigecycline. Clin Microbiol Infect. 2007;13:949-52.
7. Dubberke ER, Reske KA, Seiler S, Hink T, Kwon JH, Burnham CA. Risk factors for acquisition and loss of Clostridium difficile colonization in hospitalized patients. Antimicrob Agents Chemother. 2015;59:4533-43.
8. Quale J, Landman D, Saurina G, Atwood E, DiTore V, Patel K. Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci. Clin Infect Dis. 1996;23:1020-25.
9. Rice LB, Eckstein EC, DeVente J, Shlaes DM. Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center. Clin Infect Dis. 1996;23:118-24.
10. Adams DA, Riggs M, Donskey CJ. Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and non-epidemic Clostridium difficile in the cecal contents of mice. Antimicrob Agents Chemother. 2007;51:2674-8.
11. Jump RL, Li Y, Pultz MJ, Kypriotakis G, Donskey CJ. Tigecycline exhibits inhibitory activity against Clostridium difficile in the colon of mice and does not promote growth or toxin production. Antimicrob Agents Chemother. 2011;55:546-9.
12. Wilcox MH, Brown A, Freeman J. Faecal concentrations of piperacillin and tazobactam in elderly patients. J Antimicrob Chemother. 2001;48:141-56.
13. Nord CE, Brismar B, Kasholm-Tengve B, Tunevall G. Effect of piperacillin/tazobactam treatment on human bowel microflora. Antimicrob Chemother. 1993;31:61-5.
14. Currie BP, Lemos-Filho L. Evidence for biliary excretion of vancomycin into stool during intravenous therapy: potential implications for rectal colonization with vancomycin-resistant enterococci. Antimicrob Agents Chemother. 2004;48:4427-9.
15. Jump RL, Riggs MM, Sethi AK, Pultz MJ, Ellis-Reid T, Riebel W, et al. Multi-hospital outbreak of Clostridium difficile-associated disease, Cleveland, Ohio, USA. Emerg Infect Dis. 2010;16:827-9.
16. Nerandzic MM, Donskey CJ. An effective and reduced cost modified selective medium for isolation of Clostridium difficile. J Clin Microbiol. 2009;47:397-400.
17. Borriello SP, Barclay FE. An in-vitro model of colonisation resistance to Clostridium difficile infection. J Med Microbiol. 1986;21:299-309.
18. Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159:702-6.
19. Baines SD, Freeman J, Wilcox MH. Effects of piperacillin/tazobactam on Clostridium difficile growth and toxin production in a human gut model. J Antimicrob Chemother. 2005;55:974-82.
20. Sullivan A, Edlund C, Nord CE. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis. 2001;1:101-14.
21. Stiefel U, Pultz NJ, Harmoinen J, Koski P, Lindevall K, Helfand MS, et al. Oral administration of beta-lactamase preserves colonization resistance of piperacillin-treated mice. J Infect Dis. 2003;188:1605-9.
22. Abujamel T, Cadnum JL, Jury LA, Sunkesula VC, Kundrapu S, Jump RL, et al. Defining the vulnerable period for re-establishment of Clostridium difficile colonization after treatment of C. difficile infection with oral vancomycin or metronidazole. PLoS One. 2013;8(10):e76269.
23. Hensgens MPM, Goorhuis A, Dekkers OM, Kuijper EJ. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. J Antimicrob Chemother. 2012;67:742-8.